Close Menu

NEW YORK – Inivata said on Thursday that it has partnered with Maverick Therapeutics to use Inivata's Radar (Residual Disease and Recurrence) assay to detect and monitor residual disease and recurrence in patients enrolled in Maverick's Phase I/II clinical study for its MVC-101 drug candidate.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.